Estimation application downloads and cost
Description
HepBuzz drives awareness among healthcare professionals on labeled indications of the required dosage regimen to manage chronic HCV & HBV infections, simplified therapy options for prescribers via: HCV-Genotype & Liver status; HBV- HBeAg Type, Patient type and Laboratory parameters.
HepBuzz also renders a real-time guide for prescribers to check and validate drug-drug interactions with an interactive approach to approved product related information; namely special warnings and precautions.
Clinical calculators will enable doctors to make evidence based decisions to manage their patients. The dosage regimen, drug drug interactions and interactive product monograph is for the use of health care professionals in India only.
Read more
HepBuzz also renders a real-time guide for prescribers to check and validate drug-drug interactions with an interactive approach to approved product related information; namely special warnings and precautions.
Clinical calculators will enable doctors to make evidence based decisions to manage their patients. The dosage regimen, drug drug interactions and interactive product monograph is for the use of health care professionals in India only.
HepBuzz screenshorts
ASO analyse HepBuzz app for iPhone and iPad
No search terms founded
Competitors of HepBuzz application
Application availability
Available in countries
| Country | Price |
|---|---|
| India | free |
Available for devices
iPad2Wifi, iPad23G, iPhone4S, iPadThirdGen, iPadThirdGen4G, iPhone5, iPodTouchFifthGen, iPadFourthGen, iPadFourthGen4G, iPadMini, iPadMini4G, iPhone5c, iPhone5s, iPadAir, iPadAirCellular, iPadMiniRetina, iPadMiniRetinaCellular, iPhone6, iPhone6Plus, iPadAir2, iPadAir2Cellular, iPadMini3, iPadMini3Cellular, iPodTouchSixthGen, iPhone6s, iPhone6sPlus, iPadMini4, iPadMini4Cellular, iPadPro, iPadProCellular, iPadPro97, iPadPro97Cellular, iPhoneSE, iPhone7, iPhone7Plus, iPad611, iPad612, iPad71, iPad72, iPad73, iPad74, iPhone8, iPhone8Plus, iPhoneX,Other apps from Mylan Inc.
